Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin for the year ending March 31, 2024: 45.76%

Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin is 45.76% for the year ending March 31, 2024, a -3.54% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin for the year ending March 31, 2023 was 47.44%, a -8.71% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin for the year ending March 31, 2022 was 51.96%, a 2.99% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin for the year ending March 31, 2021 was 50.45%, a -11.07% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Gross Profit Margin for the year ending March 31, 2020 was 56.73%, a -0.40% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years